17 alpha-hydroxyprogesterone caproate, HIV, and preterm birth

Affiliations

¹ Zvitambo Institute for Maternal and Child Health Research, Harare, Zimbabwe. Electronic address: r.ntozini@zvitambo.com.
² Zvitambo Institute for Maternal and Child Health Research, Harare, Zimbabwe; Blizard Institute, Queen Mary University of London, London, UK.

Comment

Robert Ntozini et al. Lancet HIV. 2021 Oct.

. 2021 Oct;8(10):e600-e601.

doi: 10.1016/S2352-3018(21)00181-8. Epub 2021 Sep 9.

¹ Zvitambo Institute for Maternal and Child Health Research, Harare, Zimbabwe. Electronic address: r.ntozini@zvitambo.com.
² Zvitambo Institute for Maternal and Child Health Research, Harare, Zimbabwe; Blizard Institute, Queen Mary University of London, London, UK.

No abstract available

Conflict of interest statement

We declare no competing interests.

Weekly 17 alpha-hydroxyprogesterone caproate to prevent preterm birth among women living with HIV: a randomised, double-blind, placebo-controlled trial.
Price JT, Vwalika B, Freeman BL, Cole SR, Saha PT, Mbewe FM, Phiri WM, Peterson M, Muyangwa D, Sindano N, Mwape H, Smithmyer ME, Kasaro MP, Rouse DJ, Goldenberg RL, Chomba E, Stringer JSA. Price JT, et al. Lancet HIV. 2021 Oct;8(10):e605-e613. doi: 10.1016/S2352-3018(21)00150-8. Epub 2021 Sep 9. Lancet HIV. 2021. PMID: 34509197 Free PMC article. Clinical Trial.